ISR News and Press, IsoRay Inc.

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed b...

C omp any’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced N ew ticker symbol to be NYSE American: CATX RICHLAND,...

The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful complet...

RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockhold...

RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholder...

Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned unti...

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned unti...

Isoray, Inc. (ISR) Q1 2023 Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular Targeting Jonathan Hunt - CFO Conference Call Participants Mike Ott - O...

IsoRay press release ( NYSE: ISR ): Q1 GAAP EPS of -$0.03 misses by $0.02 . Revenue of $1.72M (-32.8% Y/Y) misses by $1.41M . For further details see: IsoRay GAAP EPS of -$0.03 misses by $0.02, revenue of $1.72M misses by $1.41M